HEAL:LSE:LSE-iShares Healthcare Innovation UCITS ETF USD (Acc) (USD)

ETF | Others |

Last Closing

USD 7.4075

Change

0.00 (0.00)%

Market Cap

USD 1.03B

Volume

0.11M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

+1.15 (+0.41%)

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

-0.63 (-0.93%)

USD 292,109.19B
0R1O:LSE Amazon.com Inc.

-2.50 (-1.25%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-2.16 (-1.72%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.19 (-1.05%)

USD 608.02B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.14 (-1.01%)

USD 608.02B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

-29.25 (-1.44%)

USD 321.87B
0QZK:LSE Coca-Cola Co.

-0.25 (-0.39%)

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B

ETFs Containing HEAL:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.76% 23% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.76% 21% F 34% F
Trailing 12 Months  
Capital Gain -0.90% 17% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.90% 16% F 33% F
Trailing 5 Years  
Capital Gain 15.34% 43% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.34% 40% F 52% F
Average Annual (5 Year Horizon)  
Capital Gain 6.79% 60% D- 64% D
Dividend Return 6.79% 59% D- 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.96% 20% F 32% F
Risk Adjusted Return 23.44% 49% F 59% D-
Market Capitalization 1.03B 80% B- 62% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.